Post-IPO Equity - immatics biotechnologies
Investment Firm
Overview
Immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy.
Announced Date
Sep 11, 2023
Funding Type
Post Ipo Equity
Highlights
Location
Europe
Social
Investor Lead
Participant Investors
1
| Investor Name |
|---|
Round Details and Background
immatics biotechnologies raised an undisclosed amount on 2023-09-11 in Post-IPO Equity
Immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy.
Company Funding History
13
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Oct 15, 2013 |  Series D - immatics biotechnologies | 3 | - | 16.2M |
| Sep 21, 2010 | Series C - immatics biotechnologies | 4 | - | 71.2M |
| Feb 11, 2004 | Series A - immatics biotechnologies | 7 | - | 9.9M |
| Feb 08, 2007 | Series B - immatics biotechnologies | 7 | - | 52.1M |
Recent Activity
There is no recent news or activity for this profile.